Literature DB >> 10365136

The differential expression of proinflammatory cytokines IL-6, IL-8 and TNF-alpha in renal cell carcinoma.

B König1, F Steinbach, B Janocha, A Drynda, M Stumm, C Philipp, E P Allhoff, W König.   

Abstract

Recent observations indicate that an antiinflammatory process may play a role in the metastatic cascade of renal cell carcinoma (RCC). Therefore, we compared the expression of cytokines from primary human RCC cultures, from established renal carcinoma cells and those from corresponding proximal renal tubulus cells. For this purpose the different cell types were treated with well defined and with bacterial substances such as the lipopolysaccharide, the staphylococcal enterotoxin B, a superantigen, or a combination of the calcium ionophore A23187 and phorbol 12-myristate-13-acetate. The resulting cell supernatants were analyzed for the proinflammatory cytokines (TNF-alpha, IL-6), the chemotactic active interleukin-8 as well as cytokines from T-helper type I (IL-2, IFN-gamma, IL-12) and type II (IL-4, IL-10). In parallel, the expression of cytokine-specific m-RNA was analyzed by multiplex-PCR. Our results clearly demonstrate that among the various cytokines analyzed a predominant release of TNF-alpha, IL-8 and IL-6 is obtained. The remainder cytokines were not detected independent whether molecular biology or cytokine release experiments were applied. Expression of the cytokines was dependent on the degree of malignancy. Among the applied stimuli, only the activation with calcium ionophore/phorbolester modulated cytokine expression and release. While TNF-alpha was induced from normal renal cells by up to 300% (2000 + 120 ng/10(5) cells) a pronounced suppression of TNF-alpha was observed in dependence on the malignancy of the cell line. In contrast, the cytokines IL-6 and IL-8 were significantly upregulated in malignant cells unlike in normal renal cells. These data suggest a differential role of the various cytokines derived from normal or tumor cells. Detailed studies will allow the understanding of the distinct roles of cytokines in renal carcinoma disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10365136

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

Review 1.  Role of chemokines in renal cell carcinoma.

Authors:  Jaspreet S Parihar; Hari S G R Tunuguntla
Journal:  Rev Urol       Date:  2014

2.  Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes.

Authors:  Weiqi Tan; Michelle A T Hildebrandt; Xia Pu; Maosheng Huang; Jie Lin; Surena F Matin; Pheroze Tamboli; Christopher G Wood; Xifeng Wu
Journal:  J Urol       Date:  2011-09-23       Impact factor: 7.450

3.  Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis.

Authors:  Jeffrey C Gahan; Miguel Gosalbez; Travis Yates; Ezekiel E Young; Diogo O Escudero; Andrew Chi; Michael Garcia-Roig; Ramgopal Satyanarayana; Mark S Soloway; Vincent G Bird; Vinata B Lokeshwar
Journal:  J Urol       Date:  2012-01-15       Impact factor: 7.450

4.  Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations.

Authors:  Ainhoa-M Figel; Dorothee Brech; Petra U Prinz; Ulrike K Lettenmeyer; Judith Eckl; Adriana Turqueti-Neves; Josef Mysliwietz; David Anz; Nicole Rieth; Niklas Muenchmeier; Alexander Buchner; Stefan Porubsky; Sabine I Siegert; Stephan Segerer; Peter J Nelson; Elfriede Noessner
Journal:  Am J Pathol       Date:  2011-05-18       Impact factor: 4.307

5.  Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.

Authors:  Yana G Najjar; Patricia Rayman; Xuefei Jia; Paul G Pavicic; Brian I Rini; Charles Tannenbaum; Jennifer Ko; Samuel Haywood; Peter Cohen; Thomas Hamilton; C Marcela Diaz-Montero; James Finke
Journal:  Clin Cancer Res       Date:  2016-10-31       Impact factor: 12.531

6.  Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.

Authors:  William S Holland; Clifford G Tepper; Jose E Pietri; Danielle C Chinn; David R Gandara; Philip C Mack; Primo N Lara
Journal:  Cancer Chemother Pharmacol       Date:  2011-06-05       Impact factor: 3.333

7.  Circulating obesity-driven biomarkers are associated with risk of clear cell renal cell carcinoma: a two-stage, case-control study.

Authors:  Qinchuan Wang; Huakang Tu; Meiling Zhu; Dong Liang; Yuanqing Ye; David W Chang; Yin Long; Xifeng Wu
Journal:  Carcinogenesis       Date:  2019-10-16       Impact factor: 4.944

8.  Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma.

Authors:  Huimin An; Yu Zhu; Huyang Xie; Yidong Liu; Weisi Liu; Qiang Fu; Dingwei Ye; Jiejie Xu
Journal:  Tumour Biol       Date:  2015-10-27

9.  The treatment of advanced renal cell cancer with high-dose oral thalidomide.

Authors:  J Stebbing; C Benson; T Eisen; L Pyle; K Smalley; H Bridle; I Mak; F Sapunar; R Ahern; M E Gore
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

10.  A sesquiterpene quinone, 5-Epi-smenospongine, promotes TNF-α production in LPS-stimulated RAW 264.7 Cells.

Authors:  Taiko Oda; Weifang Wang; Kazuyo Ukai; Takahiro Nakazawa; Masataka Mochizuki
Journal:  Mar Drugs       Date:  2007-10-30       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.